[go: up one dir, main page]

AU2001275438A1 - Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof - Google Patents

Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Info

Publication number
AU2001275438A1
AU2001275438A1 AU2001275438A AU7543801A AU2001275438A1 AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1 AU 2001275438 A AU2001275438 A AU 2001275438A AU 7543801 A AU7543801 A AU 7543801A AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1
Authority
AU
Australia
Prior art keywords
proteins
fixed
viral capsid
stable
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275438A
Inventor
Robert Garcea
C. Richard Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of AU2001275438A1 publication Critical patent/AU2001275438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Novel acetone- or alcohol-fixed viral capsid proteins, bacteria-containing, and papillomavirus L1-GST fusion proteins are described. These proteins are useful in vaccine preparation and as diagnostics.
AU2001275438A 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof Abandoned AU2001275438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21652600P 2000-07-06 2000-07-06
US60/216,526 2000-07-06
PCT/US2001/018701 WO2002004007A2 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2001275438A1 true AU2001275438A1 (en) 2002-01-21

Family

ID=22807390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275438A Abandoned AU2001275438A1 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Country Status (7)

Country Link
US (1) US7279306B2 (en)
EP (1) EP1305039B1 (en)
AT (1) ATE418997T1 (en)
AU (1) AU2001275438A1 (en)
DE (1) DE60137230D1 (en)
ES (1) ES2317910T3 (en)
WO (1) WO2002004007A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CN1665528B (en) 2002-07-05 2013-05-15 弗利亚生物技术公司 adjuvant virus particles
EP1784145B1 (en) 2004-08-30 2011-08-10 Neville Alleyne Implant for the treatment of ligaments and tendons
CA2578113A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AT503690A1 (en) 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US20100047264A1 (en) 2006-11-15 2010-02-25 Folia Biotech Inc. Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
WO2009055491A2 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US8469961B2 (en) 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US20120045479A1 (en) * 2008-10-17 2012-02-23 Sievers Robert E Dry Powder Formulations, Vaccines and Methods
CN102449479B (en) 2009-05-07 2015-11-25 安科健康公司 Identify high-grade or ≥CIN2 for early and late detection, screening and diagnosis of human papillomavirus (HPV) and HPV-related cancers
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
CN111000991B (en) * 2019-12-20 2023-04-21 浙江普康生物技术股份有限公司 Coxsackie virus A group 6 recombinant subunit protein vaccine and preparation method thereof
CN112472821B (en) * 2020-11-19 2022-11-18 北京大学 Application of protein nanoparticles in preparation of VSV (VSV virus) resistant product

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5475099A (en) * 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
PT809700E (en) * 1994-10-07 2006-09-29 Univ Loyola Chicago PARTICLES SIMILAR TO PAPILLOMAVIRUS AND FUSEOUS PROTEINS, AND METHODS FOR THEIR PRODUCTION
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
DE122007000015I2 (en) * 1997-09-05 2008-01-24 Medimmune Inc Method for in vitro disassembly and reassembly of papillomavirus virus-like particles (vlps)
WO2000050447A1 (en) * 1999-02-24 2000-08-31 Acorda Therapeutics Carbohydrate epitope mimic peptides and uses thereof
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
DE19925199A1 (en) * 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy

Also Published As

Publication number Publication date
DE60137230D1 (en) 2009-02-12
US7279306B2 (en) 2007-10-09
EP1305039B1 (en) 2008-12-31
EP1305039A2 (en) 2003-05-02
WO2002004007A3 (en) 2002-04-18
WO2002004007A9 (en) 2002-10-10
ATE418997T1 (en) 2009-01-15
US20070212374A1 (en) 2007-09-13
WO2002004007A2 (en) 2002-01-17
ES2317910T3 (en) 2009-05-01

Similar Documents

Publication Publication Date Title
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
TR200001842T2 (en) Papilloma virus capsomer vaccine formulations- methods of use.
WO1999033868A3 (en) Human papillomavirus vaccine
DE69535018D1 (en) PAPILLOMA VIRUS VACCINE
PT1526172E (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU7545801A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
AU4981101A (en) Subtilisin variants
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
DE60037450D1 (en) FUNF-HELIX PROTEIN
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
MXPA02007478A (en) Human immunodeficiency virus vaccine.
WO2004101598A3 (en) Insertion of furin protease cleavage sites in membrane proteins and uses thereof
AU2002228650A1 (en) Gas dehydration using membrane and potassium formate solution
TW200505501A (en) CCI-779 lyophilized formulations
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
AU5608798A (en) Formulations of recombinant papillomavirus vaccines
AU2002212555A1 (en) Yeast derived vaccine against ipnv
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
MXPA02003328A (en) Vaccine.
GB2379446A (en) Cells,culture methods and their uses
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP1309342A4 (en) PRODUCTION OF CHIMERIC HUMAN PAPILLOMAVIRUS
AUPO023496A0 (en) Modified small RNA viruses